THE ANABOLICPROTOCOL
SteroidsHigh risk

Dihydroboldenone (DHB)

Also known as: DHB, 1-Testosterone, Dihydroboldenon, 5alpha-Hydroxyboldenone, 1-Testo, Dihydroboldenone Cypionate

Own compound rather than a boldenone ester — relates to boldenone as DHT does to testosterone. Strong anabolic effect without aromatization, notorious for severe injection-site pain.

Substance family

DHT derivatives

Derived from dihydrotestosterone. They do not convert to estradiol, so no water retention — but also no estrogen of their own. Finasteride is useless against their hair loss, because they are already past the step it blocks. Hardest on the lipid profile.

Effects on

Which outcomes this substance acts on — descriptive, not a recommendation.

Strain profile

Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.

Liver
low
Kidneys
medium
Blood lipids
high
Hematocrit
high
Blood pressure
medium
Hormonal axis
high

Ester variants

Same active substance, same risk profile — only release rate and injection rhythm differ. The ester determines the timing, not the effect.

VariantHalf-lifeInjection interval
CypionateDHB CypThe most common form. Fewer injections, which matters given how painful they tend to be.~5–6 days2× / week
PropionateDHB PropMore controllable, but the higher injection frequency multiplies the injection-site pain this compound is known for.~2 daysEvery 2 days

The ester also determines how long the substance stays active after the last injection — relevant when planning a recovery phase.

Dosing & protocols by goal

Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.

Not medically indicated

Medical

Dose

Frequency

Cycle length

No human-medical indication. DHB was never developed as a medicine and circulates only through underground labs.

Lean mass — Advanced

Advanced

Dose

200–400 mg / week

Frequency

Cypionate 2× / week, propionate every 2 days

Cycle length

8–12 weeks

Alongside a testosterone base. Doses stay moderate because injection-site pain, not the effect, is usually what limits the cycle.

Higher doses

Advanced

Dose

> 400 mg / week

Frequency

Varies

Cycle length

Varies

The injection volume required makes this rarely practicable — the local reactions become the limiting factor before the systemic side effects do.

Supraphysiological doses carry significant health risks and are not legal without a medical indication. This information serves education and harm reduction, not as a usage recommendation. Accompanying blood work and — where relevant — a post-cycle plan (PCT) are essential. See the disclaimer.

Side effect & countermeasure

Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.

Problem

Severe injection-site pain, the defining practical problem

Countermeasure

DHB is notorious for local reactions that can last for days — pain, swelling, hardening. Inject slowly into large muscles, rotate sites systematically, and plan the interval so an area has recovered. Distinguish it from infection: pain increasing after several days with redness, warmth and fever needs medical attention.

Problem

Severe drop in HDL, rise in LDL

Countermeasure

As a non-aromatizing compound it hits the lipid profile hard. Cardio, omega-3 and citrus bergamot as the base; with strongly deteriorated values, ezetimibe or pitavastatin under medical guidance. Measure a baseline before starting. If a statin is started, CoQ10 belongs alongside it — statins deplete it through the same pathway.

Problem

Elevated hematocrit

Countermeasure

Cardio and adequate hydration; donate blood if markedly elevated. Check hematocrit and hemoglobin every 6–8 weeks. Nattokinase supports fibrinolysis but does not lower the cell count — donation remains the measure that works.

Problem

Estradiol falls too low (joint pain, low libido, low mood)

Countermeasure

DHB does not aromatize — unlike boldenone, from which it is derived. A testosterone base is what supplies estradiol; do not add an aromatase inhibitor on top without measuring.

Problem

Confusion with boldenone

Countermeasure

DHB is not a boldenone ester but a separate compound with a different profile: boldenone aromatizes, DHB does not. Dosing schemes and expectations from boldenone do not transfer.

Problem

Elevated blood pressure and strain on the kidneys

Countermeasure

Measure blood pressure at home, drink plenty, monitor creatinine and cystatin C. Medically, telmisartan, amlodipine or lisinopril, and low-dose tadalafil.

Problem

Underground-lab quality only

Countermeasure

There is no pharmaceutical-grade product. Purity and concentration vary considerably, and poor solvent quality makes the injection pain worse. Only sources with an independent analysis.

Overview

Dihydroboldenone, almost always abbreviated to DHB, is regularly mistaken for a boldenone ester. It is not. The relationship is the same as between testosterone and DHT: DHB is 5-alpha-reduced boldenone, a separate molecule with its own profile.

That distinction has practical consequences. Boldenone aromatizes, DHB does not. Boldenone acts slowly over a long ramp-up, DHB noticeably faster. Anyone transferring dosing schemes or expectations from one to the other will end up with a different substance than intended.

Mechanism of Action

DHB arises when boldenone is reduced by the 5-alpha-reductase enzyme — the same enzyme that converts testosterone to DHT. The additional double bond that boldenone carries relative to testosterone remains, which is why DHB is also known as 1-testosterone.

Binding to the androgen receptor is strong, and the anabolic effect is correspondingly pronounced — reported as stronger than testosterone at comparable doses. Because it cannot be converted to estradiol, there is no water retention, which produces the dry, hard appearance it is used for.

The absence of aromatization has the same consequence here as with all non-aromatizing compounds: without a testosterone base, no functioning estradiol level remains. Joint pain, loss of libido and flat mood under DHB are usually a sign of estradiol that is too low, not of the substance itself.

Injection-site pain is a property of the compound rather than of a particular product. It is caused by the substance itself and by the high concentration required, and it distinguishes DHB from almost every other injectable in this field.

Typical Context

DHB is used in lean mass phases and preparation phases, alongside a testosterone base and over eight to twelve weeks. Doses sit in the two to four hundred milligram range per week.

The point that determines practical use is not the effect but the tolerability at the injection site. Reports of pain lasting several days, hardening and swelling are the rule rather than the exception, and they are the reason many people abandon a planned cycle. This is worth knowing before the first injection, because it changes how the cycle has to be planned: fewer, larger muscles, systematic rotation, and enough interval for a site to recover.

There is no pharmaceutical-grade DHB. Everything in circulation comes from underground laboratories, which makes both purity and the quality of the solvent a factor — and poor solvent quality makes the pain considerably worse.

Side Effects & Risks

  • Severe injection-site pain, swelling and hardening lasting days
  • Severe drop in HDL, rise in LDL
  • Elevated hematocrit
  • Estradiol too low without a testosterone base
  • Elevated blood pressure
  • Strain on the kidneys
  • Suppression of natural testosterone production
  • Acne, accelerated hair loss with a genetic predisposition
  • Consistently underground-lab quality

Blood Work & Monitoring

  • Lipid profile (LDL, HDL, triglycerides) — baseline, during and after
  • Hematocrit & hemoglobin — every 6–8 weeks
  • Estradiol (sensitive) — watch for levels that are too low
  • Total/free testosterone — to check the base
  • Blood pressure — measured at home
  • Creatinine and cystatin C — kidney function
  • Liver values (ALT, AST, GGT)

Harm-Reduction Notes

  • Do not confuse it with boldenone; it is a different compound with a different profile
  • Plan the injection-site pain in: large muscles, systematic rotation, adequate interval
  • Distinguish normal pain from infection — increasing pain after several days with redness, warmth or fever needs a doctor
  • A testosterone base is not optional; without it there is no estradiol
  • Measure a lipid baseline before starting; the HDL drop is pronounced
  • Only sources with an independent analysis — solvent quality directly affects tolerability
  • A post-cycle plan belongs in place before the first injection

Legal status by region

Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.

RegionRegulatory status
United StatesSchedule III controlled substanceNo approved human indication; distribution is a federal offence.
EU / UKNot approved for human useSome compounds exist only as veterinary products or not at all.
Canada / AustraliaControlled substanceNo human indication.
Parts of Asia & Latin AmericaGrey market, largely unregulatedAvailability does not imply pharmaceutical quality — underground-lab product dominates.
Competitive sportProhibited at all timesListed by WADA.
All content on this page is for information and harm-reduction purposes only. It is not medical advice, not a recommendation to purchase or use, and does not replace consulting a doctor. Legal status and enforcement vary by country and change; verifying the current rules in your own jurisdiction is your responsibility. For adults 18+ only. See the full disclaimer.